SCHEMBL3218735

SCHEMBL3218735

O=C(NCc1ccco1)c1ccc(Cl)[n+]([O-])c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.58
APBA1 Q02410 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
ALDH1A1 P00352 5/20 0.56
PKM P14618 1/20 0.56
HPGD P15428 5/20 0.54
TP53 P04637 3/20 0.54
MLYCD O95822 1/20 0.54
NPC1 O15118 1/20 0.54
MAPT P10636 1/20 0.54
TSHR P16473 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 3/20 0.53
POLB P06746 2/20 0.52
HTT P42858 1/20 0.52
HSD17B10 Q99714 1/20 0.52
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2422719 0.79 TDP1 (0.73) CACNA1BAPBA1TDP1ALDH1A1PKM
SCHEMBL3217701 0.79 CA2 (0.56) ALDH1A1HPGDTSHRRAB9ALMNA
SCHEMBL10805444 0.75 ALDH1A1 (0.63) CACNA1BAPBA1TDP1ALDH1A1HPGD
SCHEMBL4491643 0.75 TDP1 (0.75) CACNA1BAPBA1TDP1ALDH1A1PKM
SCHEMBL1490952 0.74 HPGD (0.76) TDP1ALDH1A1HPGDTP53MLYCD
SCHEMBL4672305 0.74 TDP1 (0.69) CACNA1BAPBA1TDP1ALDH1A1PKM
SCHEMBL8404655 0.74 TDP1 (0.74) TDP1ALDH1A1PKMHPGDTP53
SCHEMBL3230330 0.74 CXCR2 (0.67) TP53MAPTSMN1; SMN2LMNAPOLB
SCHEMBL95374 0.74 TDP1 (0.73) CACNA1BAPBA1TDP1ALDH1A1PKM
SCHEMBL6023593 0.74 TDP1 (1.00) TDP1ALDH1A1PKMHPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063105-A1 PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES UCB SA (GB) 2010-03-11 US disclosed
US-7141590-B2 Pharmaceutical uses and synthesis of nicotinanilide-N-oxides UCB SA (GB) 2006-11-28 US disclosed
US-20050026965-A1 Pharmaceutical uses and synthesis of nicotinanilide-N-oxides DARWIN DISCOVERY LIMITED (GB) 2005-02-03 US disclosed
WO-2002053544-A1 PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES DARWIN DISCOVERY LTD. (GB) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063105-A1 PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES NNT, NAPRT, NNMT CACNA1B 263/4885APBA1 3833/4885TDP1 2606/4885
US-20050026965-A1 Pharmaceutical uses and synthesis of nicotinanilide-N-oxides NNT, NAPRT, NNMT CACNA1B 263/4885APBA1 3833/4885TDP1 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.